Scholarlink

Background <p>Respiratory system cancers, primarily encompassing lung cancer, tracheal cancer, bronchial cancer, and laryngeal cancer, severely jeopardize patients’ lives. Therefore, this study aimed to investigate the global burden of respiratory system cancers in 2022 using the GLOBOCAN 2022 database, to inform global prevention strategies.</p> Methods <p>This study extracted data of respiratory system cancers from GLOBOCAN 2022, stratified into two subsets: laryngeal cancer (C32) and tracheal, bronchial, and lung cancers (C33, C34). It analyzed the incidence, mortality, and age-standardized rates (ASR) of both subsets across world regions, HDI levels, genders, and age groups, and projected their disease burden from 2022 to 2050.</p> Results <p>For tracheal, bronchial, and lung cancers (C33, C34), Hungary had the highest age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR). For laryngeal cancer alone (C32), India had the highest global ASIR and ASMR. Very high HDI regions had the highest ASR for the combined cancers. Males had higher incidence and mortality than females across regions and HDI strata for both subsets. Incidence and mortality rose markedly after age 40, with faster growth in males. Projection results indicated that by 2050, the male incidence and mortality rates of tracheal, bronchial, and lung cancers would increase by 87.97% and 94.75%, respectively. For laryngeal cancer, the number of male incident cases and male deaths was expected to grow by 72.53% and 81.33%, respectively.</p> Conclusion <p>This study, grounded in the GLOBOCAN 2022 database, elucidated the respiratory system cancers (lung cancer, tracheal cancer, bronchial cancer, and laryngeal cancer) global burden. It thereby furnished theoretical references for subsequent preventive measures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Global burden of respiratory system cancers in 2022 and 2050: incidence and mortality estimates from GLOBOCAN

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Yuhua Wang,
  • Feng Yu,
  • Feng Qiu,
  • Ke Fang

摘要

Background

Respiratory system cancers, primarily encompassing lung cancer, tracheal cancer, bronchial cancer, and laryngeal cancer, severely jeopardize patients’ lives. Therefore, this study aimed to investigate the global burden of respiratory system cancers in 2022 using the GLOBOCAN 2022 database, to inform global prevention strategies.

Methods

This study extracted data of respiratory system cancers from GLOBOCAN 2022, stratified into two subsets: laryngeal cancer (C32) and tracheal, bronchial, and lung cancers (C33, C34). It analyzed the incidence, mortality, and age-standardized rates (ASR) of both subsets across world regions, HDI levels, genders, and age groups, and projected their disease burden from 2022 to 2050.

Results

For tracheal, bronchial, and lung cancers (C33, C34), Hungary had the highest age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR). For laryngeal cancer alone (C32), India had the highest global ASIR and ASMR. Very high HDI regions had the highest ASR for the combined cancers. Males had higher incidence and mortality than females across regions and HDI strata for both subsets. Incidence and mortality rose markedly after age 40, with faster growth in males. Projection results indicated that by 2050, the male incidence and mortality rates of tracheal, bronchial, and lung cancers would increase by 87.97% and 94.75%, respectively. For laryngeal cancer, the number of male incident cases and male deaths was expected to grow by 72.53% and 81.33%, respectively.

Conclusion

This study, grounded in the GLOBOCAN 2022 database, elucidated the respiratory system cancers (lung cancer, tracheal cancer, bronchial cancer, and laryngeal cancer) global burden. It thereby furnished theoretical references for subsequent preventive measures.